Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis

Fig. 4

SF-MSC treatment enhanced Treg induction. A Representative flow cytometry analysis for the detection of Tregs in murine peripheral blood. Gated on lymphocytes in peripheral blood nucleated cells (upper left panel). Gated on CD3+/CD4+ T cells in the lymphocytes (upper right panel). Gray-filled gate indicates CD3+/CD4+/CD25+/Foxp3+ Tregs (lower panel). B The percentages of Tregs in murine blood or lungs before or at 2 or 4 days after MSC injection to healthy mice (n = 5 per group). C The percentages of Tregs in murine blood or lung before or at 6, 10, or 14 days after BLM OA followed by injection of MSCs (i.e., at 2, 6, or 10 days after MSCs injection) or PBS (i.e., at 2, 6, or 10 days after PBS injection) (n = 4–6 per group). D The percentages of FoxP3+/CD4+ T cells in the murine thymus before or at 6 or 10 days after BLM OA (n = 4–5 per group). Data are presented as the mean ± SD for normal distribution, or the median with interquartile range for non-normal distribution. *P < 0.05. ***P < 0.005. ****P < 0.001. E Schematic summary of the dynamics of serum TGF-β1, number of Tregs in the blood and lungs in BLM-treated mice followed by SF-MSC or PBS intravenous administration

Back to article page